
Investigating the effect of IV iron treatment on haemoglobin, haematocrit, and iron biomarkers in HFrEF patients, this retrospective study compares outcomes in those treated with and without SGLT2 inhibitors. SGLT2i users demonstrated significantly greater increases in haemoglobin (+0.57 g/dl) and haematocrit (+1.64%), indicating a potential erythropoietic synergy.
Like
Save
Share